miércoles, 16 de julio de 2025
A million veterans gave DNA to aid health research. Scientists worry the data will be wasted.
https://www.news-medical.net/news/20250716/A-million-veterans-gave-DNA-to-aid-health-research-Scientists-worry-the-data-will-be-wasted.aspx
One of the world's biggest genetic databases comprises DNA data donated over the years by more than a million retired military service members. It's part of a project run by the Department of Veterans Affairs.
Understanding resistance to EGFR targeted therapies in head and neck cancers and breast cancer ++++++
Understanding resistance to EGFR targeted therapies in head and neck cancers and breast cancer
Understanding resistance to EGFR targeted therapies in head and neck cancers and breast cancerA new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights into RTK dependent and independent mechanisms."
https://www.news-medical.net/news/20250710/Understanding-resistance-to-EGFR-targeted-therapies-in-head-and-neck-cancers-and-breast-cancer.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=breast_cancer_newsletter_11_july_2025
Watch: She’s at high risk of breast cancer. She moved, and her screening costs soared.
https://www.news-medical.net/news/20250710/Watch-Shee28099s-at-high-risk-of-breast-cancer-She-moved-and-her-screening-costs-soared.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=breast_cancer_newsletter_11_july_2025
Watch: She’s at high risk of breast cancer. She moved, and her screening costs soared.Kelli Reardon undergoes an MRI twice a year to screen for breast cancer, a measure she said she must take to protect her health. Her mother died of the disease at age 48, putting Reardon at higher risk, and Reardon has dense breast tissue, which makes it harder to detect a growth through a mammogram.
Metabolic enzyme PHGDH found to play a surprising role in breast cancer immunity
https://www.news-medical.net/news/20250707/Metabolic-enzyme-PHGDH-found-to-play-a-surprising-role-in-breast-cancer-immunity.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=breast_cancer_newsletter_11_july_2025
Metabolic enzyme PHGDH found to play a surprising role in breast cancer immunityMacrophages are immune cells with a split personality: some fight tumors, while others help them grow. In breast cancer, most macrophages fall into the latter camp—dubbed M2-like—fueling tumor progression and dampening immune responses.
Energy waves on cancer cell surfaces linked to tumor growth and aggressiveness
https://www.news-medical.net/news/20250709/Energy-waves-on-cancer-cell-surfaces-linked-to-tumor-growth-and-aggressiveness.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=breast_cancer_newsletter_11_july_2025
In a bid to better understand how cancer cells power their explosive growth and spread, scientists at Johns Hopkins Medicine say they have shed new light on the location and function of power-generating waves on the covering, or membrane, of these cells.
KAIST scientists develop tool to fight drug resistance in cancer
https://www.news-medical.net/news/20250708/KAIST-scientists-develop-tool-to-fight-drug-resistance-in-cancer.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=breast_cancer_newsletter_11_july_2025
KAIST scientists develop tool to fight drug resistance in cancerOne of the biggest obstacles in cancer treatment is drug resistance in cancer cells. Conventional efforts have focused on identifying new drug targets to eliminate these resistant cells, but such approaches can often lead to even stronger resistance.
Preeclampsia in pregnancy reduces risk of some cancers but raises endometrial cancer odds
https://www.news-medical.net/news/20250707/Preeclampsia-in-pregnancy-reduces-risk-of-some-cancers-but-raises-endometrial-cancer-odds.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=breast_cancer_newsletter_11_july_2025
Preeclampsia in pregnancy reduces risk of some cancers but raises endometrial cancer oddsWomen with preeclampsia in their first pregnancy had a lower risk of developing breast, cervical, and lung cancer later in life, but a higher risk of endometrial cancer. The large Nordic cohort study also found that siblings of women with PE had a modestly reduced risk of cancer, particularly lung cancer.
Confusion persists over breast cancer screening guidelines +++++
https://www.news-medical.net/news/20250703/Confusion-persists-over-breast-cancer-screening-guidelines.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=breast_cancer_newsletter_11_july_2025
Mammograms can find cancer early before symptoms appear. Regular screening decreases the risk of dying from breast cancer. But a recent survey question by the Annenberg Public Policy Center shows that some Americans appear to be confused about when women with an average risk of breast cancer should begin a regimen of regular mammograms.
Artificial intelligence enhances radiologists’ accuracy in breast cancer detection
https://www.news-medical.net/news/20250708/Artificial-intelligence-enhances-radiologistse28099-accuracy-in-breast-cancer-detection.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=breast_cancer_newsletter_11_july_2025
Excess weight linked to breast cancer risk in postmenopausal women with cardiovascular disease
https://www.news-medical.net/news/20250707/Excess-weight-linked-to-breast-cancer-risk-in-postmenopausal-women-with-cardiovascular-disease.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=breast_cancer_newsletter_11_july_2025
Amino acid metabolism in breast cancer as a driver of disease and therapeutic target
https://www.news-medical.net/news/20250707/Amino-acid-metabolism-in-breast-cancer-as-a-driver-of-disease-and-therapeutic-target.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=breast_cancer_newsletter_11_july_2025
Evolutionary mutation weakens human immune response to solid tumors
https://www.news-medical.net/news/20250703/Evolutionary-mutation-weakens-human-immune-response-to-solid-tumors.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=breast_cancer_newsletter_11_july_2025
Hormone Therapy Unlocked: Case Studies in Diagnosing and Managing Hypoactive Sexual Desire Disorder and Menopausal Hormone Therapy Wednesday, Aug. 13, from 11:10 a.m. to 2:30 p.m. ET
https://www.dhaj7-cepo.com/content/hormone-therapy-special-feature?utm_source=newsletter&utm_medium=email&utm_campaign=july2025
Watch the discussion on timely approaches to menopause and perimenopause care from February’s Clinical Communities Speaker Series, then join the panelists live to dissect real-world case studies on the complexities of diagnosing and managing hypoactive sexual desire disorder and menopausal symptoms in women.
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial +...
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00092-0/abstract?dgcid=raven_jbs_etoc_feature_landia
Editorial
p635
Reassessing driving safety in diabetes
The Lancet Diabetes & Endocrinology
https://www.thelancet.com/journals/landia/issue/vol13no8/PIIS2213-8587(25)X0008-5
martes, 15 de julio de 2025
Researchers find gut bacteria rapidly soak up ‘forever chemicals’
https://www.news-medical.net/news/20250701/Researchers-find-gut-bacteria-rapidly-soak-up-e28098forever-chemicalse28099.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_7_july_2025
Can our gut bacteria help clear dangerous ‘forever chemicals’ from our bodies? New research reveals certain microbes rapidly sequester PFAS, offering hope for microbiome-based solutions against toxic environmental exposures.
Study explores how a familiar spice tackles the toughest cancer cells
https://www.news-medical.net/news/20250627/Study-explores-how-a-familiar-spice-tackles-the-toughest-cancer-cells.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_7_july_2025
Could a kitchen spice help stop colorectal cancer before it starts? New research shows curcumin selectively attacks the stem-like cells that fuel early tumors, pointing to a promising, low-risk addition to current prevention strategies.
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00209-8/abstract?utm_campaign=update-lanonc&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanonc&_hsenc=p2ANqtz-_pK1rMKRU_vMqovSxowWmCDtJXQrdE8g1EEQfy8By2UAS8ZaQD24nx93FxrE_enTglT5nPLamtn91j1GR6_R7ZnxIiYg&_hsmi=371230603&utm_content=371146860&utm_source=hs_email
Editorial p817 Politics and pharma: hurdles in UK science ambitions The Lancet Oncology +...
https://www.thelancet.com/journals/lanonc/issue/vol26no7/PIIS1470-2045(25)X0007-3
Person-focused approach explains distinct autism genetic subtypes
https://www.news-medical.net/news/20250715/Person-focused-approach-explains-distinct-autism-genetic-subtypes.aspx
New study shows that autism is not one condition, but four, each driven by different genes and brain development patterns, helping to reshape diagnosis and care.
GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss +++
https://www.news-medical.net/health/GLP-1-and-Diet-Evidence-Based-Strategies-for-Better-Weight-Loss.aspx
What Happens to Your Body When You Skip Meals?
https://www.news-medical.net/health/What-Happens-to-Your-Body-When-You-Skip-Meals.aspx
Saffron’s Evolving Place in Modern Medicine - From Tradition to Evidence
https://www.news-medical.net/health/Saffrone28099s-Evolving-Place-in-Modern-Medicinee28094From-Tradition-to-Evidence.aspx
lunes, 14 de julio de 2025
Intergenerational association of adverse childhood experiences and perinatal mental health in adult female offspring: evidence from the longitudinal grandmothers, mothers, and their Children's health study in China +...
https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(25)00116-6/fulltext?dgcid=hubspot_update_feature_updatealerts_lanwpc&utm_campaign=update-lanwpc&utm_medium=email&_hsenc=p2ANqtz-9jGcRbrCjK8wkg_d0fEtgd6eQywVAIUSppgWPfLBj0M7Az9tYPUF2QN_WYoaRMUUGY7Rr3sgV8B98gbleUNee2BiFVNw&_hsmi=371100144&utm_content=370502769&utm_source=hs_email
Editorial +...
Menstrual reform: cultural roots of delayed endometriosis diagnosis in the Asia–Pacific region
The Lancet Regional Health – Western Pacific
https://www.thelancet.com/journals/lanwpc/issue/vol59nonull/PIIS2666-6065(25)X0007-9
US measles cases hit highest level in more than 30 years, CDC data shows By Greg Norman Fox News Published July 9, 2025 1:05pm EDT
US measles cases hit highest level in more than 30 years, CDC data shows
The last time measles cases in the US were this high was in 1992, according to CDC
Greg Norman By Greg Norman Fox News
Published July 9, 2025 1:05pm EDT
https://www.foxnews.com/health/us-measles-cases-hit-highest-level-more-than-30-years-cdc-data-shows
‘I’m a cardiologist – here’s how the summer heat could damage your heart’ By Angelica Stabile Fox News Published July 12, 2025 5:00am EDT | Updated July 11, 2025 5:00am EDT
‘I’m a cardiologist – here’s how the summer heat could damage your heart’
Recognizing key warning signs can help prevent heat-related cardiac events, expert says
Angelica Stabile By Angelica Stabile Fox News
Published July 12, 2025 5:00am EDT | Updated July 11, 2025 5:00am EDT
https://www.foxnews.com/health/im-cardiologist-heres-how-summer-heat-could-damage-your-heart
Arizona resident dies of pneumonic plague, the first deadly case in area in nearly 20 years By Brie Stimson Fox News Published July 12, 2025 10:19pm EDT
Arizona resident dies of pneumonic plague, the first deadly case in area in nearly 20 years
The disease, once responsible for killing millions during the Black Death of the 14th century, is now rare in the US and treatable with antibiotics
By Brie Stimson Fox News
Published July 12, 2025 10:19pm EDT
https://www.foxnews.com/health/arizona-resident-dies-from-pneumonic-plague-first-deadly-case-area-nearly-20-years
Always running late? A mental health condition could be to blame, experts say By Khloe Quill Fox News Published July 14, 2025 5:00am EDT
Always running late? A mental health condition could be to blame, experts say
Time blindness may be culprit behind chronic lateness — how to handle it
By Khloe Quill Fox News
Published July 14, 2025 5:00am EDT
https://www.foxnews.com/health/always-running-late-mental-health-condition-could-blame-experts-say
domingo, 13 de julio de 2025
sábado, 12 de julio de 2025
Burning Up? A Guide To Recognizing And Managing Heat Illness Zina Semenovskaya, MD, FAWM; Sage Wiener, MD | June 20, 2025 ++++
https://reference.medscape.com/slideshow/heat-illness-6004448?ecd=wnl_critimg_250711_mscpref_etid7557978&uac=148436CN&impID=7557978#1
Heat Stroke
https://emedicine.medscape.com/article/166320-overview?ecd=wnl_critimg_250711_mscpref_etid7557978&uac=148436CN&impID=7557978
Heat-Related Deaths in Europe Will Skyrocket by 2099
Ute Eppinger
https://www.medscape.com/viewarticle/heat-related-deaths-europe-will-skyrocket-2099-2025a10003r6?ecd=wnl_critimg_250711_mscpref_etid7557978&uac=148436CN&impID=7557978
February 13, 2025
Higher Heat Index Tied to Adverse Kidney Transplant Outcomes
Nancy A. Melville
https://www.medscape.com/viewarticle/higher-heat-index-tied-adverse-kidney-transplant-outcomes-2025a100090r?ecd=wnl_critimg_250711_mscpref_etid7557978&uac=148436CN&impID=7557978
April 16, 2025
Prevalence and severity of chronic kidney disease in a population with type 1 diabetes from a United States health system: a real-world cohort study +...
https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(25)00140-1/fulltext?dgcid=raven_jbs_etoc_feature_lanam
Editorial
No safe line: the human cost of dismantling LGBTQ+ youth support services
The Lancet Regional Health – Americas
https://www.thelancet.com/journals/lanam/issue/vol47nonull/PIIS2667-193X(25)X0006-5
Satellite Symposia in conjunction with the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting CME/CNE/CPE Houston, TX
https://events.medscapelive.org/website/87553/
Join us in Houston this September for 3 dynamic, live symposia. These activities are planned and provided by Medical Learning Institute Inc and Medscape Oncology. Engage with leading experts as they explore the latest research and treatments in hematologic malignancies. Each session offers interactive discussions, lively panel debates, and audience Q&A. Browse the sessions below and reserve your spot today.
Hormone Therapy Unlocked Wednesday, August 13, 2025 11:10 a.m. to 2:30 p.m. ET
https://www.dhaj7-cepo.com/content/hormone-therapy-special-feature?utm_source=adobe&utm_medium=email&utm_campaign=july092025
Join expert panelists for a two-part discussion on unlocking the benefits of hormone therapy
After a replay of the exciting session on the latest approaches to menopause and perimenopause care from the Clinical Communities Speaker Series event held earlier this year, join the panelists live for an exploration of real-world case studies on navigating the complexities of diagnosing and managing hypoactive sexual desire disorder and menopausal symptoms in women.
viernes, 11 de julio de 2025
Witness to a Revolution: A Blood Cancer Expert’s Long View Randy Dotinga July 11, 2025 + +...
https://www.medscape.com/viewarticle/witness-revolution-blood-cancer-experts-long-view-2025a1000ie8
European Hematology Association (EHA) 2025 Annual Meeting
https://www.medscape.com/viewcollection/37800
Cerebral palsy + + +...
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00686-5/abstract?dgcid=raven_jbs_etoc_feature_lancet
Social prescribing: bringing community back to health?
The Lancet
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01435-7/fulltext?dgcid=raven_jbs_etoc_email
Jul 12, 2025
Volume 406Number 10499p103-202
https://www.thelancet.com/journals/lancet/issue/vol406no10499/PIIS0140-6736(25)X0028-3
jueves, 10 de julio de 2025
Most baby foods are sweet, smooth, and poorly aligned with health advice, review finds
Despite their popularity and promises, commercial baby foods are often packed with sugar and lack the diversity infants need, raising concerns for parents who trust the packaging over public health advice.
https://www.news-medical.net/news/20250709/Most-baby-foods-are-sweet-smooth-and-poorly-aligned-with-health-advice-review-finds.aspx
Phthalate exposure from plastics and cardiovascular disease: global estimates of attributable mortality and years life lost +...
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(25)00174-4/fulltext?dgcid=raven_jbs_etoc_feature_ebiom
The careful use of opioids and alternatives for pain management
eBioMedicine
https://www.thelancet.com/journals/ebiom/issue/vol117nonull/PIIS2352-3964(25)X0006-2
Exercise for colon cancer: from supportive care to therapy The Lancet Gastroenterology & Hepatology +...
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00206-7/fulltext?dgcid=raven_jbs_etoc_email
Volume 10, Issue 8
Aug 2025
Volume 10Number 8p701-778, e10
vhttps://www.thelancet.com/journals/langas/issue/vol10no8/PIIS2468-1253(25)X0007-8
Is pneumococcal vaccination required for new residents of care facilities for older adults? The Lancet Healthy Longevity +...
Risk of cardiovascular disease among cancer survivors: systematic review and meta-analysis +...
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00206-8/fulltext?dgcid=hubspot_update_feature_updatealerts_eclinm&utm_campaign=update-eclinm&utm_medium=email&_hsenc=p2ANqtz-9I8W3kkTJPjHtC9GQaa1T1wDPlp_bl6ogw38I86GJXT3nSBSLg0hGYW7fmyBMF-m95AFjOg0--INDJSjKMgCsWD2BUrA&_hsmi=370561096&utm_content=370499787&utm_source=hs_email
The bloom and the breathless: the rising burden of pollen allergy
eClinicalMedicine
https://www.thelancet.com/journals/eclinm/issue/vol84nonull/PIIS2589-5370(25)X0005-5
miércoles, 9 de julio de 2025
Research-driven neonatology for equitable neonatal health The Lancet Child & Adolescent Health +...
Redefining Alzheimer’s development by mapping disease sequences
https://www.news-medical.net/news/20250709/Redefiningc2a0-Alzheimere28099s-development-by-mapping-disease-sequences.aspx
By mapping millions of real patient health records, UCLA scientists have uncovered four unique and predictable routes to Alzheimer’s, reshaping how we detect, understand, and potentially prevent the condition.
Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00046-3/abstract?utm_campaign=update-lanres&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanres&_hsenc=p2ANqtz-9w9tpPdthNdthDdYGcc1Eu3qfo7q2_6bhaCU-PjPnONCKG9ReBCI_gtg2uab4DOAYPLt_5GIL0QEfxMm2JYlM4nBhAfw&_hsmi=370165620&utm_content=370130586&utm_source=hs_email
Jul 2025
Volume 13Number 7p569-654, e33-e37
https://www.thelancet.com/journals/lanres/issue/vol13no7/PIIS2213-2600(25)X0007-2
Global burden of vision impairment due to age-related macular degeneration, 1990–2021, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021
Global burden of vision impairment due to age-related macular degeneration, 1990–2021, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00143-3/fulltext?dgcid=hubspot_update_feature_updatealerts_langlo&utm_campaign=update-langlo&utm_medium=email&_hsenc=p2ANqtz-9TNFSp1HIJxTgimp0cPIWBwuIDNvdCt97AxKh4tFvjrPrNdobf0YJUe6NmMDRoGo8bysa7D7DI4cQeLjqXVXp9NALrNg&_hsmi=370151790&utm_content=370131563&utm_source=hs_email
Jul 2025
Volume 13Number 7e1151-e1326
https://www.thelancet.com/journals/langlo/issue/vol13no7/PIIS2214-109X(25)X0007-3
martes, 8 de julio de 2025
Morning workouts can boost weight loss if one key habit is followed, experts say By Angelica Stabile Fox News Published July 7, 2025 5:00am EDT
Morning workouts can boost weight loss if one key habit is followed, experts say
Trainers reveal critical balance between early exercise and proper sleep
Angelica Stabile By Angelica Stabile Fox News
Published July 7, 2025 5:00am EDT
https://www.foxnews.com/health/morning-workouts-can-boost-weight-loss-one-key-habit-followed-experts-say
Miley Cyrus reveals the 'powerful' therapy that helped her conquer stage fright By Reem Amro Fox News Published July 6, 2025 5:00am EDT
Miley Cyrus reveals the 'powerful' therapy that helped her conquer stage fright
The pop icon credits EMDR for her confident stage presence: "Saved my life'
By Reem Amro Fox News
Published July 6, 2025 5:00am EDT
https://www.foxnews.com/health/miley-cyrus-reveals-powerful-therapy-helped-her-conquer-stage-fright
Stanford scientists 'totally surprised' by potential Parkinson's treatment discovery By Khloe Quill Fox News Published July 7, 2025 5:20pm EDT
Stanford scientists 'totally surprised' by potential Parkinson's treatment discovery
Experimental treatment could improve patient condition, not just stabilize symptoms, researchers say
By Khloe Quill Fox News
Published July 7, 2025 5:20pm EDT
https://www.foxnews.com/health/stanford-scientists-totally-surprised-potential-parkinsons-treatment-discovery
Children's health declines in last 17 years, study finds By Stephen Sorace Fox News Published July 8, 2025 8:00am EDT
Children's health declines in last 17 years, study finds
Research shows American kids more likely to die than children in comparable countries
By Stephen Sorace Fox News
Published July 8, 2025 8:00am EDT
https://www.foxnews.com/health/childrens-health-declines-last-17-years-study-finds
Never smoked? You could still be at risk of developing lung cancer, doctors warn By Melissa Rudy Fox News Published July 8, 2025 5:00am EDT | Updated July 8, 2025 5:51am EDT
Never smoked? You could still be at risk of developing lung cancer, doctors warn
Medical experts note concerning trend in patients without traditional smoking history
Melissa Rudy By Melissa Rudy Fox News
Published July 8, 2025 5:00am EDT | Updated July 8, 2025 5:51am EDT
https://www.foxnews.com/health/never-smoked-you-could-still-risk-developing-lung-cancer-doctors-warn
Around the Web Today’s Daily Digest of stories culled from the Internet and excerpted +++
‘Designer baby’ startup: Controversal germline editing company Bootstrap Bio raising money for germline gene editing launch
https://geneticliteracyproject.org/2025/07/07/designer-baby-startup-controversal-germline-editing-company-bootstrap-bio-raising-money-for-germline-gene-editing-launch/?mc_cid=f2630965f0&mc_eid=b73600b7ac
Hyper-communication: How our phones, emails and social media are reshaping evolution
https://geneticliteracyproject.org/2025/07/07/hyper-communication-how-our-phones-emails-and-social-media-are-reshaping-evolution/?mc_cid=f2630965f0&mc_eid=b73600b7ac
Olympics on Steroids: The juiced enhanced games are coming in 2026. But that’s not the most bizarre gimmick
https://geneticliteracyproject.org/2025/07/07/olympics-on-steroids-the-juiced-enhanced-games-are-coming-in-2026-but-thats-not-the-most-bizarre-gimmick/?mc_cid=f2630965f0&mc_eid=b73600b7ac
lunes, 7 de julio de 2025
Neem - Evidence-Based Health Benefits +++
Neem - Evidence-Based Health Benefits
https://www.news-medical.net/health/Neem-Evidence-Based-Health-Benefits.aspx
What is the TLC Diet?
https://www.news-medical.net/health/What-is-the-TLC-Diet.aspx
Tridecanoic Acid (C13): The Odd-Chain Fatty Acid With Big Implications
Tridecanoic acid (C13) is a rare, odd-chain saturated fatty acid produced mainly by gut and rumen microbes, entering metabolic pathways via β-oxidation to support gluconeogenesis and the TCA cycle. Although scarcely detected in plasma, emerging research suggests C13 could serve as a sensitive biomarker for diet-microbiome interactions and may have distinct metabolic and anti-inflammatory effects.
https://www.news-medical.net/medical/articles
New smart bandage detects real-time biomarkers in chronic wounds To help clinicians monitor slow-healing chronic wounds, researchers created the iCares device and tested it in 20 people with a variety of wounds.New smart bandage detects real-time biomarkers in chronic wounds To help clinicians monitor slow-healing chronic wounds, researchers created the iCares device and tested it in 20 people with a variety of wounds.
Navigating the complexities of the rare glomerular diseases C3G and primary IC-MPGN
https://us02web.zoom.us/webinar/register/WN_fG5Gj5r8QQadimusIa8Awg#/registration
Join Our Glomerular Diseases RARE Rev-inar on July 8th!
We are thrilled to invite you to our 20th RARE Rev-inar, focusing on glomerular diseases, specifically C3G and primary IC-MPGN. This vital discussion, supported by Apellis Pharmaceuticals, promises to be highly informative and engaging.
Date: Tuesday, 8th July 2025
Time: 3.30 PM BST | 10:30 AM EST |
Where: Online – register here: https://bit.ly/GlomerularDiseasesWebinar
Our expert panel includes:
Dr. Bradley Dixon: Professor of paediatrics-nephrology specialising in kidney diseases linked to complement system abnormalities.
Lexi Pencis: Mother of Collette, diagnosed with C3 Glomerulopathy (C3G) at age six, offering a parent's perspective on managing intensive care pathways.
Christina Gilchrist ("BLIND CHICK LIVING"): With over 20 years of experience navigating dialysis and two kidney transplants, co-manages a popular dialysis support group and hosts a podcast.
Michael Gilchrist: Christina's husband and primary caregiver, co-managing their dialysis kidney support group.
Michelle Williams: Diagnosed with plasma cell neoplasm and primary IC-MPGN in September 2023.
The webinar will cover:
Understanding the Journey: Diagnosis and early experiences with glomerular diseases.
Living with and Managing the Disease: Insights into daily life, care pathways, and unmet needs.
Hope for the Future: Discussions on research, support, and necessary changes in healthcare.
Don't miss this opportunity to gain valuable insights and participate in a live Q&A session with our esteemed panellists. A link to articles and experiences from our digital spotlight, including an educational infographic, will be shared in the chat during the webinar.
domingo, 6 de julio de 2025
One Team, One Goal: The Key to Better Patient Outcomes in Early Breast Cancer Management Authors: Fatima Cardoso, MD, FESMO, ESCO; Nadia Harbeck, MD, PhD; Shani Paluch, MBBS, MSc
https://www.medscape.org/viewarticle/1002593?sso=true&uac=148436CN&src=mkmcmr_reeng_recap_mscpedu_activity
One Team, One Goal: The Key to Better Patient Outcomes in Early Breast Cancer Management
Below are some key learning points to help reinforce the impact of this activity.
☑ HR+/HER2- breast cancer
• For a 28-year old woman with cT2 cN1 cM0, HR+/HER2-negative breast cancer with germline BRCA wild-type, therapy recommendations would be pre-operative endocrine therapy, based on data from the ADAPT trial
• In this patient, considering that she was ypT2 ypN1 after neoadjuvant therapy and surgery, adjuvant therapy with either exemestane or tamoxifen, ovarian function suppression plus an aromatase inhibitor is warranted
• These recommendations are supported by long-term data from the SOFT and TEXT trials, as well as monarchE and NATALEE
• The ADAPTcycle trial which is ongoing will also serve to inform if chemotherapy can be substituted for endocrine therapy based on recurrence risk scores and response to endocrine therapy
☑ HER2-positive early breast cancer
• For a 55-year-old patient with Grade 3, ER 80%, PR 30%, HER2 IHC3+, Ki-67 60% cT2 (2.5 cm) cN0 disease, ESMO currently recommends neoadjuvant therapy with trastuzumab + pertuzumab + chemotherapy
• This recommendation is supported by long-term (11.3 years) follow-up data from APHINITY, which showed sustained improvement with this regimen vs trastuzumab + chemotherapy
• If after surgery, the patient still has residual disease, the patient should continue to receive adjuvant T-DM1 (KATHERINE data), with the potential for also receiving neratinib (ExteNET data)
• Current ongoing trials which could inform treatment decisions in the future include DESTINY-Breast05 (adjuvant T-DXd compared to T-DM1) and DESTINY-Breast11 (neoadjuvant T-DXd vs standard of care)
☑ Triple-negative early breast cancer
• For a patient with Grade 3, ER-/PR-/HER2-negative, Ki-67 80%, with germline BRCA mutation, ESMO currently recommends neoadjuvant therapy with chemotherapy + pembrolizumab, followed by surgery, and if non-PCR, adjuvant pembrolizumab or olaparib
• These recommendations are based on
◦ KEYNOTE-522 (phase 3), which showed significantly improved outcomes with pembrolizumab vs placebo, on a backbone of chemotherapy
◦ OlympiA (phase 3), which showed significantly improved outcomes with olaparib vs placebo
• Multiple clinical trials with various antibody-drug conjugates are ongoing in this setting
Virtual Simulations: Managing the Patient With HR+/HER2- Early Breast Cancer Through a Multidisciplinary Approach Authors: Manali Bhave, MD; Jane Meisel, MD
https://www.medscape.org/viewarticle/1002474?sso=true&uac=148436CN&src=mkmcmr_reeng_recap_mscpedu_activity
Virtual Simulations: Managing the Patient With HR+/HER2- Early Breast Cancer Through a Multidisciplinary Approach
Below are some key learning points to help reinforce the impact of this activity.
☑ ASSESSING RISK OF RECURRENCE IN PATIENTS WITH EBC
• Several factors must be considered when assessing a patient’s risk of recurrence. Key prognostic factors include age, tumor size, tumor grade, nodal involvement, and biomarker expression.
• Gene expression profiling can also provide additional insight about an individual’s risk for recurrence. Multiple gene expression profiling assays are currently available for patients with early-stage, HR-positive/HER2-negative breast cancer. Each of these assays differs with respect to the type of information they provide and the specific patient populations used for assay validation.
• Current guidelines from National Comprehensive Cancer Network® (NCCN®), ASCO, and the European Society for Medical Oncology (ESMO) should be followed when considering whether to test and which assay is most appropriate.
☑ GUIDELINE-BASED ADJUVANT TREATMENT OF HR-POSITIVE/HER2-NEGATIVE EBC
• NCCN and ESMO guidelines recommend considering adjuvant radiation therapy for those undergoing breast conserving surgery. The use of adjuvant chemotherapy should be based on risk for recurrence, including use of genomic assays when appropriate to identify patients most likely to benefit. [NCCN,v6.2024;Loibl,2024]
• NCCN guidelines recommend adjuvant endocrine therapy ± a CDK 4/6 inhibitor in HR-positive/HER2-negative EBC as follows [NCCN,v6.2024]:
◦ For patients who are premenopausal at diagnosis
▪ Tamoxifen for 5 years (± ovarian suppression or ablation) (both Category 1); consider adjuvant abemaciclib in eligible patients
∙ If considering extended endocrine therapy in a postmenopausal patient after 5 years of tamoxifen, then can switch to AI for 5 years (Category 1) or continue tamoxifen for an additional 5 years
∙ If considering extended endocrine therapy in a premenopausal patient after 5 years of tamoxifen, consider tamoxifen for an additional 5 years or no further endocrine therapy
OR
▪ An aromatase inhibitor (AI) for 5 years plus ovarian suppression or ablation (Category 1); consider adjuvant abemaciclib or ribociclib in eligible patients; then consider an additional 3 to 5 years of AI with continuation of ovarian suppression or ablation if patient remains premenopausal
• For patients who are postmenopausal at diagnosis
◦ An AI for 5 years (Category 1); consider adjuvant abemaciclib or ribociclib in eligible patients; consider additional 3 to 5 years of AI
OR
◦ An AI for 2 to 3 years (Category 1); consider adjuvant abemaciclib or ribociclib in eligible patients; then follow with tamoxifen to complete 5 years of endocrine therapy total (Category 1)
OR
◦ Tamoxifen for 2 to 3 years, followed by either an AI to complete 5 years of endocrine therapy total (Category 1) or an AI for 5 years (Category 2B)
OR
◦ Tamoxifen for 4.5 to 6 years, followed by either an AI for 5 years (Category 1) or tamoxifen for an additional 5 years
OR
◦ For patients with contraindication or intolerance to an AI, tamoxifen for 5 years (Category 1) with consideration to extend tamoxifen for 10 years total
• Current breast cancer guidelines recommend consideration of 2 years of adjuvant abemaciclib (ASCO, ESMO, and NCCN) or 3 years of adjuvant ribociclib (ASCO and NCCN) in combination with endocrine therapy in patients with moderate-risk to high-risk disease.
• Use of an adjuvant PARP inhibitor, olaparib, should be considered for patients with high-risk, early-stage HER2-negative breast cancer who also carry a germline BRCA1/2 mutation.
☑ ADDITION OF CDK-TARGETED THERAPY TO ADJUVANT ENDOCRINE THERAPY
• Adjuvant CDK 4/6 inhibitors (eg, abemaciclib, ribociclib) have been shown to further reduce the risk of recurrence in high-risk, HR-positive/HER2-negative early breast cancer in combination with adjuvant endocrine therapy.
• Abemaciclib
◦ Guidelines from NCCN, ASCO, and ESMO recommend abemaciclib for node-positive, high-risk, HR-positive/HER2-negative EBC. [NCCN,v6.2024;Freedman,2024;Loibl,2024] NCCN defines high risk as [NCCN,v6,2024]:
▪ 4 positive nodes OR
▪ 1-3 positive nodes AND grade 3 OR
▪ 1-3 positive nodes AND tumor size ≥5 cm
◦ ASCO guidelines also include a definition of high risk as 1 to 3 positive nodes and Ki-67 ≥20%. [Freedman,2024] ESMO guidelines recommend consideration of abemaciclib for patients with Stage III or high-risk Stage II disease. [Loibl,2024]
• Ribociclib
◦ Ribociclib was evaluated in the phase 3 NATALEE trial comparing a nonsteroidal AI (with goserelin for premenopausal patients) with or without 3 years of ribociclib.
◦ Eligibility criteria differed from the monarchE trial and included patients with HR-positive/HER2-negative EBC with either Stage III, Stage II with positive nodes (N1), or Stage II node-negative disease that was Grade 3 or had a high Oncotype Dx score or high-risk Mammaprint and/or Ki-67 ≥20%. [Slamon,2024]
◦ Based on these data, 3 years of ribociclib therapy is currently approved by both the FDA and EMA in combination with adjuvant endocrine therapy for patients with HR-positive/HER2-negative, high-risk EBC. ASCO and NCCN guidelines recommend consideration of these therapies in patients who meet the eligibility criteria for the NATALEE trial, defining high-risk as:
▪ Node-positive OR
▪ Node-negative AND tumor size >5 cm OR
▪ Node-negative AND tumor size 2 to 5 cm AND Grade 3 OR
▪ Node-negative AND tumor size 2 to 5 cm AND Grade 2 AND high genomic risk OR Ki-67 ≥20%
☑ Monitoring and Management of AEs
• Patients receiving CDK4/6 inhibitor therapy should be educated on potential AEs, as well as how and when to notify their healthcare teams when side effects do occur. Complete blood counts and liver function should be assessed at baseline and monitored during therapy or as clinically indicated.
• Electrocardiograms (ECGs) should also be used to monitor for QTc prolongation with ribociclib. Patients should also be closely monitored for signs and symptoms of venous thromboembolism, interstitial lung disease, and pneumonitis (eg, hypoxia, cough, dyspnea).
Synbiotics May Lower Anxiety | Single Dose Psilocybin Treats Depression +++++ ++++ +++ +
INTEGRATIVE THERAPIES
Prebiotics, Probiotics May Lower Anxiety, Depression
https://www.medscape.com/viewarticle/probiotics-prebiotics-tied-decreased-depression-anxiety-2025a1000fec?ecd=mkm_ret_250705_mscpmrk_psych_anxiety_etid7538034&uac=148436CN&impID=7538034
How One Dose of Psilocybin Treats Depression
https://www.medscape.com/viewarticle/how-one-dose-psilocybin-treats-depression-2025a1000g2w?ecd=mkm_ret_250705_mscpmrk_psych_anxiety_etid7538034&uac=148436CN&impID=7538034
Novel Method Eases Pain, Anxiety in ED
https://www.medscape.com/viewarticle/music-therapy-eases-pain-and-anxiety-emergency-department-2025a1000apm?ecd=mkm_ret_250705_mscpmrk_psych_anxiety_etid7538034&uac=148436CN&impID=7538034
Program May Reduce Anxiety in COPD
https://www.medscape.com/viewarticle/digital-mindfulness-program-may-reduce-anxiety-patients-2025a1000gmw?ecd=mkm_ret_250705_mscpmrk_psych_anxiety_etid7538034&uac=148436CN&impID=7538034
One Dose Eases Cancer Depression
https://www.medscape.com/viewarticle/one-psilocybin-dose-eases-cancer-depression-over-long-term-2025a1000gd9?ecd=mkm_ret_250705_mscpmrk_psych_anxiety_etid7538034&uac=148436CN&impID=7538034
ANXIETY & CORMORBIDITIES
Anxiety & Alcohol Use: The Complex Interplay
https://www.medscape.com/viewarticle/two-diagnoses-one-patient-how-treat-alcohol-use-and-mental-2025a1000czn?ecd=mkm_ret_250705_mscpmrk_psych_anxiety_etid7538034&uac=148436CN&impID=7538034
Depression, Anxiety Rates With Chronic Pain
https://www.medscape.com/viewarticle/high-global-rates-comorbid-depression-anxiety-chronic-pain-2025a10007t1?ecd=mkm_ret_250705_mscpmrk_psych_anxiety_etid7538034&uac=148436CN&impID=7538034
The Therapy After Stroke Tied to Better Psych Outcome
https://www.medscape.com/viewarticle/early-talk-therapy-after-stroke-tied-better-psych-outcome-2025a1000geo?ecd=mkm_ret_250705_mscpmrk_psych_anxiety_etid7538034&uac=148436CN&impID=7538034
Leg Weakness, Fatigue, Cognitive Issues With Anxiety, Depression: What’s Your Dx?
https://reference.medscape.com/viewarticle/1001934?ecd=mkm_ret_250705_mscpmrk_psych_anxiety_etid7538034&uac=148436CN&impID=7538034
TREATMENT ESSENTIALS
Antidepressant Meds: How Much Do You Know?
https://reference.medscape.com/viewarticle/986771?ecd=mkm_ret_250705_mscpmrk_psych_anxiety_etid7538034&uac=148436CN&impID=7538034
Antidepressants Effective for GAD
https://www.medscape.com/viewarticle/confirmed-antidepressants-effective-generalized-anxiety-2025a100032i?ecd=mkm_ret_250705_mscpmrk_psych_anxiety_etid7538034&uac=148436CN&impID=7538034
Anxiety Disorders: What to Know
https://emedicine.medscape.com/article/286227-overview?ecd=mkm_ret_250705_mscpmrk_psych_anxiety_etid7538034&uac=148436CN&impID=7538034
US DRUG SPOTLIGHT
Risperidone
https://reference.medscape.com/drug/perseris-risperdal-consta-risperidone-342986?ecd=mkm_ret_250705_mscpmrk_psych_anxiety_etid7538034&uac=148436CN&impID=7538034
Suscribirse a:
Entradas (Atom)